|MDACC Study No:||2012-0543 (clinicaltrials.gov NCT No: NCT01797523)|
|Title:||A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients with Advanced or Recurrent Endometrial Carcinoma|
|Principal Investigator:||Pamela Soliman|
|Treatment Agent:||Letrozole; Metformin; RAD001|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
everolimus, letrozole, and metformin can help to control recurrent or
progressive endometrial cancer. The safety of this drug combination will also
Everolimus is designed to block a protein inside cancer cells that is involved
in cancer growth.
Letrozole is designed to block a protein from making estrogen. This may
interfere with the growth of cancer cells.
Metformin is commonly used to control blood sugar levels in patients with
diabetes. It is designed to lower insulin levels, which may slow or stop the
growth of endometrial cancer cells.